Lupin Receives Final Approval to Market Generic Ultram® ER from US FDA
Lupin Pharmaceuticals, Inc. (LPI) announced on 29th aug, 2011 that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300 mg strengths. Lupin will begin shipping its Tramadol ER shortly.